SCHEMBL2914737

SCHEMBL2914737

COc1ccc(C(=O)Nc2ccc(-c3cc(C(=O)O)ccc3C)cc2)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.61
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
MAPK14 Q16539 2/20 0.60
ALDH1A1 P00352 2/20 0.56
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA4 P22748 1/20 0.55
CA6 P23280 1/20 0.55
CA7 P43166 1/20 0.55
TPMT P51580 1/20 0.55
CA9 Q16790 1/20 0.55
CA14 Q9ULX7 1/20 0.55
PLAU P00749 1/20 0.55
RAB9A P51151 5/20 0.53
NPC1 O15118 4/20 0.53
NQO2 P16083 1/20 0.53
CASP3 P42574 1/20 0.53
SENP7 Q9BQF6 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11162884 0.85 PKM (0.82) PKMMEN1KMT2AALDH1A1CA12
SCHEMBL2906890 0.84 MAPK14 (0.65) PKMMEN1KMT2AMAPK14ALDH1A1
SCHEMBL2342219 0.82 MAPT (0.80) PKMMEN1KMT2AMAPK14ALDH1A1
SCHEMBL12394335 0.80 KMT2A (0.62) PKMMEN1KMT2AALDH1A1RAB9A
SCHEMBL2979309 0.80 CA12 (0.64) PKMMEN1KMT2AMAPK14ALDH1A1
SCHEMBL13423757 0.80 MAPK14 (0.71) MEN1KMT2AMAPK14ALDH1A1PLAU
SCHEMBL17664663 0.79 MEN1 (0.72) PKMMEN1KMT2AALDH1A1RAB9A
SCHEMBL2907501 0.79 SMN1; SMN2 (0.55) MEN1KMT2AMAPK14ALDH1A1PLAU
SCHEMBL2348198 0.78 MAPT (0.74) PKMMEN1KMT2AMAPK14ALDH1A1
SCHEMBL9339478 0.78 PKM (0.67) PKMMEN1KMT2AALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 PKM 4821/4885MEN1 3163/4885KMT2A 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.